Hepion Pharmaceuticals, Inc. (HEPA): Price and Financial Metrics
GET POWR RATINGS... FREE!
HEPA Stock Price Chart Interactive Chart >
HEPA Price/Volume Stats
| Current price | $0.73 | 52-week high | $1.33 |
| Prev. close | $0.78 | 52-week low | $0.26 |
| Day low | $0.70 | Volume | 380,512 |
| Day high | $0.81 | Avg. volume | 1,767,246 |
| 50-day MA | $0.48 | Dividend yield | N/A |
| 200-day MA | $0.60 | Market Cap | 55.63M |
Hepion Pharmaceuticals, Inc. (HEPA) Company Bio
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that has completed the Phase I clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and Tenofovir exalidex, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Latest HEPA News From Around the Web
Below are the latest news stories about HEPION PHARMACEUTICALS INC that investors may wish to consider to help them evaluate HEPA as an investment opportunity.
Anti-Cancer Potential of Rencofilstat Expanded with Results from Preclinical Multiple Myeloma Studies- Synergistic activity demonstrated with rencofilstat in combination with first line multiple myeloma drug, bortezomib - EDISON, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced positive |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time to start off the day with a breakdown of the biggest pre-market stock movers making the news on Wednesday morning! |
Presentation of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome InhibitorsEDISON, N.J., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, announced that its research collaborator, Carlos Perez-Stable, PhD, from the University of Miami Miller School of Medicine and Miami Veterans Affairs/Research |
Hepion Pharmaceuticals Receives $3.2 Million in Aggregate Non-Dilutive FundingApproximately $2.9 Million from Sale of Its New Jersey State Net Operating Losses (“NOLs”), Plus $0.3 Million from Alberta Innovation Employment GrantEDISON, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chr |
Hepion Pharmaceuticals to Present Phase 2a Rencofilstat Multiomics Data at NASH-TAG 2023EDISON, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that an abstract highlighting its lead drug candidate, rencofilstat, will be presented at the NASH-TAG 2023 Conference, |
HEPA Price Returns
| 1-mo | 143.09% |
| 3-mo | 22.67% |
| 6-mo | 30.36% |
| 1-year | -25.52% |
| 3-year | -85.91% |
| 5-year | -99.53% |
| YTD | 143.09% |
| 2022 | -73.66% |
| 2021 | -47.95% |
| 2020 | -59.14% |
| 2019 | -72.65% |
| 2018 | -90.28% |
Loading social stream, please wait...